Lipocine (LPCN) Expected to Announce Earnings on Thursday

Lipocine (NASDAQ:LPCN) is projected to release its earnings data before the market opens on Thursday, March 6th. Analysts expect Lipocine to post earnings of ($0.26) per share and revenue of $2.61 million for the quarter.

Lipocine Stock Performance

Shares of LPCN opened at $3.19 on Thursday. The stock has a market capitalization of $17.03 million, a PE ratio of -4.19 and a beta of 1.23. The company’s fifty day moving average is $4.36 and its 200 day moving average is $4.58. Lipocine has a fifty-two week low of $2.96 and a fifty-two week high of $11.79.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Lipocine in a report on Wednesday. They issued a “hold” rating on the stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.